Search Results - "Gartland, Martin"

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study by van Wyk, Jean, Ajana, Faïza, Bisshop, Fiona, De Wit, Stéphane, Osiyemi, Olayemi, Portilla Sogorb, Joaquín, Routy, Jean-Pierre, Wyen, Christoph, Ait-Khaled, Mounir, Nascimento, Maria Claudia, Pappa, Keith A, Wang, Ruolan, Wright, Jonathan, Tenorio, Allan R, Wynne, Brian, Aboud, Michael, Gartland, Martin J, Smith, Kimberly Y

“…Abstract Background The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with human immunodeficiency virus type 1…”
Get full text

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study by Moyle, Graeme J, Stellbrink, Hans-Jürgen, Compston, Juliet, Orkin, Chloe, Arribas, José R, Domingo, Pere, Granier, Catherine, Pearce, Helen, Sedani, Sangeeta, Gartland, Martin

“…Abacavir/lamivudine (ABC/3TC) and tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) are widely used as first-line antiretroviral therapies. However, there…”
Get more information

A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937 by Benn, Paul D., Zhang, Ying, Kahl, Lesley, Greene, Thomas J., Bainbridge, Veronica, Fishman, Cindy, Wen, Bo, Gartland, Martin

“…We report the safety and pharmacokinetic properties of the HIV‐1 maturation inhibitor GSK3739937 (GSK'937) in healthy participants. This was a phase I,…”
Get full text

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies by Llibre, Josep M, Hung, Chien-Ching, Brinson, Cynthia, Castelli, Francesco, Girard, Pierre-Marie, Kahl, Lesley P, Blair, Elizabeth A, Angelis, Kostas, Wynne, Brian, Vandermeulen, Kati, Underwood, Mark, Smith, Kim, Gartland, Martin, Aboud, Michael

“…Lifelong HIV antiretroviral therapy (ART) has prompted an interest in two-drug regimens to minimise cumulative drug exposure and toxicities. The safety,…”
Get full text

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial by Aboud, Michael, Kaplan, Richard, Lombaard, Johannes, Zhang, Fujie, Hidalgo, José A, Mamedova, Elmira, Losso, Marcelo H, Chetchotisakd, Ploenchan, Brites, Carlos, Sievers, Jörg, Brown, Dannae, Hopking, Judy, Underwood, Mark, Nascimento, Maria Claudia, Punekar, Yogesh, Gartland, Martin, Smith, Kimberly

“…Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of…”
Get full text

Open‐label, drug–drug interaction study between the HIV‐1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants by Zhang, Ying, Johnson, Mark, Joshi, Samit, Yazdani, Parto, Zhan, Joyce, Wen, Bo, Bainbridge, Veronica, Gartland, Martin, Lataillade, Max

“…Aims GSK3640254 (GSK'254) is an HIV‐1 maturation inhibitor with pharmacokinetics (PK) supporting once‐daily dosing. GSK'254 will be co‐administered with…”
Get full text

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials by Cahn, Pedro, Madero, Juan Sierra, Arribas, José R., Antinori, Andrea, Ortiz, Roberto, Clarke, Amanda E., Hung, Chien-Ching, Rockstroh, Jürgen K., Girard, Pierre-Marie, Sievers, Jörg, Man, Choy Y., Urbaityte, Rimgaile, Brandon, Daisy J., Underwood, Mark, Tenorio, Allan R., Pappa, Keith A., Wynne, Brian, Gartland, Martin, Aboud, Michael, van Wyk, Jean, Smith, Kimberly Y.

“…BACKGROUND:The 2-drug regimen dolutegravir + lamivudine was noninferior to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA…”
Get full text

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection by Cahn, Pedro, Sierra Madero, Juan, Arribas, José R., Antinori, Andrea, Ortiz, Roberto, Clarke, Amanda E., Hung, Chien-Ching, Rockstroh, Jürgen K., Girard, Pierre-Marie, Sievers, Jörg, Man, Choy Y., Urbaityte, Rimgaile, Brandon, Daisy J., Underwood, Mark, Pappa, Keith A., Curtis, Lloyd, Smith, Kimberly Y., Gartland, Martin, Aboud, Michael, van Wyk, Jean, Wynne, Brian

“…To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive…”
Get full text

Pharmacokinetics and tolerability of the maturation inhibitor GSK3640254 coadministered with darunavir/ritonavir and/or etravirine in healthy adults by Zhang, Ying, Joshi, Samit, Yazdani, Parto, Zhan, Joyce, Wen, Bo, Bainbridge, Veronica, Ballesteros‐Perez, Alex, Gartland, Martin, Lataillade, Max

“…Aims This phase I study investigated potential drug–drug interactions of the maturation inhibitor GSK3640254 (GSK'254) with darunavir/ritonavir (DRV/RTV)…”
Get full text

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile by Dicker, Ira, Jeffrey, Jerry L, Protack, Tricia, Lin, Zeyu, Cockett, Mark, Chen, Yan, Sit, Sing-Yuen, Gartland, Martin, Meanwell, Nicholas A, Regueiro-Ren, Alicia, Drexler, Dieter, Cantone, Joseph, McAuliffe, Brian, Krystal, Mark

“…HIV-1 maturation inhibitors (MIs) offer a novel mechanism of action and potential for use in HIV-1 treatment. Prior MIs displayed clinical efficacy but were…”
Get full text

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health by McComsey, Grace A, Lupo, Sergio, Parks, David, Poggio, Mónica Coronado, De Wet, Joseph, Kahl, Lesley P, Angelis, Kostas, Wynne, Brian, Vandermeulen, Kati, Gartland, Martin, Cupo, Michael, Aboud, Michael

“…OBJECTIVE:Bone mineral density (BMD) loss, a risk factor for osteoporosis, has been attributed to HIV infection and antiretroviral therapy (ART), including…”
Get full text

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254 by Spinner, Christoph D, Felizarta, Franco, Rizzardini, Giuliano, Philibert, Patrick, Mitha, Essack, Domingo, Pere, Stephan, Christoph J, DeGrosky, Michelle, Bainbridge, Veronica, Zhan, Joyce, Dumitrescu, Teodora Pene, Jeffrey, Jerry L, Xu, Jianfeng, Halliday, Fiona, Gan, Jianjun, Johnson, Mark, Gartland, Martin, Joshi, Samit R, Lataillade, Max

“…GSK3640254 (GSK'254) is a next-generation human immunodeficiency virus type 1 (HIV-1) maturation inhibitor with pharmacokinetics (PK) supporting once-daily…”
Get full text

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials by van Wyk, Jean, Orkin, Chloe, Rubio, Rafael, Bogner, Johannes, Baker, David, Khuong-Josses, Marie-Aude, Parks, David, Angelis, Konstantinos, Kahl, Lesley P., Matthews, Jessica, Wang, Ruolan, Underwood, Mark, Wynne, Brian, Nascimento, Maria-Claudia, Vandermeulen, Kati, Gartland, Martin, Smith, Kimberly Y.

“…BACKGROUND:The SWORD trials showed that in participants who achieved virologic suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen…”
Get full text

Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies by Aboud, Michael, Orkin, Chloe, Podzamczer, Daniel, Bogner, Johannes R, Baker, David, Khuong-Josses, Marie-Aude, Parks, David, Angelis, Konstantinos, Kahl, Lesley P, Blair, Elizabeth A, Adkison, Kimberly, Underwood, Mark, Matthews, Jessica E, Wynne, Brian, Vandermeulen, Kati, Gartland, Martin, Smith, Kimberly

“…Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to…”
Get full text

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis by Eron, Joseph, Hung, Chien-Ching, Baril, Jean-Guy, Slim, Jihad, Falcó, Vicenç, Bogner, Johannes, Maggiolo, Franco, Mills, Anthony, Sievers, Jörg, Man, Choy Y., Urbaityte, Rimgaile, Underwood, Mark, Tenorio, Allan R., Pappa, Keith A., Wynne, Brian, Koteff, Justin, Gartland, Martin, Smith, Kimberly Y., Aboud, Michael

“…BACKGROUND:To investigate antiviral potency of the 2-drug regimen (2DR) dolutegravir plus lamivudine vs the 3-drug regimen (3DR) dolutegravir plus tenofovir…”
Get full text

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy–naive adults with HIV-1 infection by Cahn, Pedro, Madero, Juan Sierra, Arribas, José R., Antinori, Andrea, Ortiz, Roberto, Clarke, Amanda E., Hung, Chien-Ching, Rockstroh, Jürgen K., Girard, Pierre-Marie, Sievers, Jörg, Man, Choy Y., Urbaityte, Rimgaile, Brandon, Daisy J., Underwood, Mark, PAPPA, Keith A., Curtis, Lloyd, Smith, Kimberly Y., Gartland, Martin, Aboud, Michael, van Wyk, Jean, Wynne, Brian

Get full text

2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies by van Wyk, Jean A, Man, Choy Y, Sievers, Jörg, Urbaityte, Rimgaile, Underwood, Mark, Tenorio, Allan R, Pappa, Keith, Wynne, Brian, Smith, Kimberly, Gartland, Martin

“…Abstract Background At Weeks 48 and 96 in the GEMINI-1 and GEMINI-2 studies (Clinicaltrials.gov: NCT02831673 and NCT02831764), the 2DR of DTG+3TC was…”
Get full text

2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies by Oglesby, Alan, Angelis, Kostas, Punekar, Yogesh, Chounta, Vasiliki, Antela, Antonio, Matthews, Jessica, Kahl, Lesley, Gartland, Martin, Wynne, Brian, Murray, Miranda, Andre Van Wyk, Jean

“…Abstract Background The SWORD-1 and SWORD-2 studies previously demonstrated that high rates of virologic suppression were maintained for 148 weeks after…”
Get full text

319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks by Kahl, Lesley, McComsey, Grace A, Coronado Poggio, Monica, Lupo, Sergio, de Wet, Joss, Parks, David A, Wynne, Brian, Gartland, Martin, Angelis, Kostas, Aylott, Alicia, Cupo, Michael, Vandermeulen, Kati, van Wyk, Jean A, Smith, Kimberly

“…Abstract Background HIV infection and antiretroviral therapy (ART), particularly tenofovir (TDF), is associated with loss of bone mineral density (BMD). The…”
Get full text

Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled results from the GEMINI studies by Eron, Joseph, Hung, Chien-Ching, Baril, Jean-Guy, Slim, Jihad, Falcó, Vicenç, Bogner, Johannes, Maggiolo, Franco, Mills, Anthony, Sievers, Jörg, Man, Choy Y., Currie, Alexander, Underwood, Mark, Tenorio, Allan, Pappa, Keith A., Wynne, Brian, Koteff, Justin, Gartland, Martin, Smith, Kimberly Y., Aboud, Michael, Paice, Alistair

Get full text